Peptide encyclopedia
Every compound indexed here carries mechanism, route of administration, half-life, legal status, and the primary sources backing every claim — graded and dated.
- Compounds
- 75
- Source links
- 249
- Therapeutic classes
- 10
- Matching filter
- 6
F·Filter
Reset allOther
Compounds outside the primary corpus classes.
6 compounds
01
Research use only
C-peptide
proinsulin C-peptide · connecting peptide · et al.
C-peptide is the cautionary tale of how a real mechanism, decades of academic interest, and multiple positive Phase II readouts can still produce a negative pivotal trial — the 'almost made it' peptide in diabetic neuropathy.
Half-life·~30 minutes plasma half-life for native human C-peptide on s…
Read entry
02
Research use only
Follistatin
FST · FS-288 · et al.
The preclinical case for follistatin in muscle hypertrophy is one of the strongest in any peptide category — and the human pharmacology of the gray-market peptide itself is essentially blank. The clinically-grounded data in this pathway sits on the antibody and gene-therapy side, where the failure track record is substantial.
Half-life·Native human FST-315 has a terminal serum half-life of appro…
Read entry
03
Research use only
Kisspeptin
KP54 · KP-54 · et al.
The strongest mechanism story in the HPG-axis-restoration class — and the smallest chronic-dosing evidence base of any peptide marketed for it.
Half-life·Kisspeptin-54 plasma half-life is approximately 27.6 minutes…
Read entry
04
Research use only
Larazotide
AT-1001 · INN-202 · et al.
Larazotide is the case study the gut-permeability peptide field has had to absorb — a positive Phase IIb signal that did not survive Phase III futility analysis, and a mechanism whose own academic literature has become contested in the same window.
Half-life·Oral, acid-resistant, designed for luminal action in the sma…
Read entry
05
Research use only
Melanotan II
MT-II · MT2 · et al.
Melanotan II is the peptide on this site with the most adverse-event case-report literature: melanoma, dysplastic nevi, priapism, rhabdomyolysis, renal infarction, persistent mucosal hyperpigmentation. The pharmacology that drove its commercial appeal is the same pharmacology that produced the FDA-approved spin-off PT-141 at a fraction of the systemic receptor exposure.
Half-life·Plasma half-life approximately 30 to 60 minutes on subcutane…
Read entry
06
Research use only
Olcegepant
BIBN 4096 BS · olcegepant
Olcegepant is the proof-of-concept that opened the CGRP-receptor antagonist class — and the molecule that did not reach the market, because intravenous-only dosing made oral formulation impossible and the first-generation oral gepants that followed (telcagepant, MK-3207) were discontinued for hepatotoxicity that the second-generation gepants were specifically engineered around.
Half-life·Terminal plasma half-life of approximately 2.5 hours after s…
Read entry